| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The molecular targets of Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside are not fully characterized. As a flavonoid glycoside, it may exert antioxidant effects through radical scavenging. It may also modulate signaling pathways involved in inflammation and cell proliferation. Its presence in Camellia oleifera seeds suggests it may contribute to the health benefits of tea seed oil. However, specific molecular targets have not been identified.
|
|---|---|
| ln Vitro |
In vitro studies of Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside are limited. As a natural glycoside, it would be expected to have antioxidant activity, similar to other flavonoid glycosides. It is a natural product found in Camellia oleifera seeds. However, specific in vitro potency data such as IC₅₀ values or assay results are not detailed in the available sources. Its primary use is as a research compound for biochemical and drug synthesis studies.
|
| ln Vivo |
Specific in vivo activity data for Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside are not available in the consulted sources. As a compound from Camellia oleifera seeds, it may have potential health benefits. However, no specific in vivo studies have been reported. Further research is needed to evaluate its pharmacokinetics and efficacy.
|
| Enzyme Assay |
No specific protocols for enzyme/receptor binding assays are available for Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside. As a natural glycoside, standard antioxidant assays such as DPPH and ABTS radical scavenging assays could be employed to assess its activity. For drug synthesis research, it may be used as a starting material or intermediate.
|
| Cell Assay |
No specific cell-based assay protocols are available for Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside. The compound is primarily used as a research compound for biochemical experiments and drug synthesis. For potential biological activity, standard cell viability or antioxidant assays could be employed using cell lines such as endothelial cells or macrophages, but none have been reported.
|
| Animal Protocol |
No specific in vivo animal experiment protocols are available for Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside. The compound is a natural product used as a research compound and is not intended for in vivo pharmacological studies. No pharmacokinetic or efficacy studies in animal models have been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside are not available. As a large, polar flavonoid glycoside with a molecular weight of 756.66 g/mol, it would be expected to have poor oral bioavailability. It may be metabolized by gut microbiota or hydrolyzed by glycosidases to release kaempferol. Detailed ADME parameters are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside are limited. As a natural flavonoid glycoside found in Camellia oleifera seeds, it is generally considered to have low toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Reports indicate that kaempferol-3-O-(2"-O-β-D-glucosyl)-β-D-rutin has been found in Hosta, Hydrangea macrophylla, and Mallow, and relevant data are available for reference.
Kaempferol-3-O-(2''-O-β-D-glucopyl)-β-D-rutinoside is a natural glycoside found in Camellia oleifera seeds. It is suitable for biochemical experiments and drug synthesis research. It is a flavonoid glycoside derived from kaempferol. It is a research compound and is not approved for any clinical indication. |
| Molecular Formula |
C33H40O20
|
|---|---|
| Molecular Weight |
756.66
|
| Exact Mass |
756.211
|
| CAS # |
55696-58-7
|
| PubChem CID |
21676305
|
| Appearance |
Off-white to light yellow solid
|
| Source |
Originated from plants: other families
|
| LogP |
-2.5
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
53
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O(C1([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])C1([H])C([H])(OC2C(C3=C(C([H])=C(C([H])=C3OC=2C2C([H])=C([H])C(=C([H])C=2[H])O[H])O[H])O[H])=O)OC([H])(C([H])([H])OC2([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])[H])O2)O[H])O[H])O[H])C([H])(C1([H])O[H])O[H]
|
| InChi Key |
VNLOLXSJMINBIS-CFRIXVKNSA-N
|
| InChi Code |
InChI=1S/C33H40O20/c1-10-19(38)23(42)26(45)31(48-10)47-9-17-21(40)25(44)30(53-32-27(46)24(43)20(39)16(8-34)50-32)33(51-17)52-29-22(41)18-14(37)6-13(36)7-15(18)49-28(29)11-2-4-12(35)5-3-11/h2-7,10,16-17,19-21,23-27,30-40,42-46H,8-9H2,1H3/t10-,16+,17+,19-,20+,21+,23+,24-,25-,26+,27+,30+,31+,32-,33-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: ~5 mg/mL (~6.6 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (0.66 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (5.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (0.66 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (5.0 mg/mL) to 900 μL of 20% SBE-β-CD physiological saline and mix well. Preparation of 20% SBE-β-CD physiological saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of physiological saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3216 mL | 6.6080 mL | 13.2160 mL | |
| 5 mM | 0.2643 mL | 1.3216 mL | 2.6432 mL | |
| 10 mM | 0.1322 mL | 0.6608 mL | 1.3216 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
